Jump to content

Methamphetamine

From Pharmacopedia
Revision as of 06:09, 13 May 2026 by MDElliottMD (talk | contribs) (Removed titration "adhd-desoxyn")
Psychostimulant, Amphetamine
Methamphetamine
Desoxyn
Methamphetamine is a CNS stimulant of the amphetamine class. It is FDA-approved (as Desoxyn) for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

<indication slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/> <indication slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

  • Attention and focusπŸ‘€ no reports yetβš•οΈ no reports yet
  • WakefulnessπŸ‘€ no reports yetβš•οΈ no reports yet
  • Motivation and driveπŸ‘€ no reports yetβš•οΈ no reports yet
  • Mild euphoriaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Decreased appetite/AnorexiaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Dry mouthπŸ‘€ no reports yetβš•οΈ no reports yet
  • Elevated heart rate / blood pressureπŸ‘€ no reports yetβš•οΈ no reports yet
  • InsomniaπŸ‘€ no reports yetβš•οΈ no reports yet
  • IrritabilityπŸ‘€ no reports yetβš•οΈ no reports yet
  • AnxietyπŸ‘€ no reports yetβš•οΈ no reports yet
  • HeadacheπŸ‘€ no reports yetβš•οΈ no reports yet
  • Weight lossπŸ‘€ no reports yetβš•οΈ no reports yet
  • PalpitationsπŸ‘€ no reports yetβš•οΈ no reports yet
  • Jaw clenching / bruxismπŸ‘€ no reports yetβš•οΈ no reports yet
  • Stereotyped behaviorsπŸ‘€ no reports yetβš•οΈ no reports yet
  • AgitationπŸ‘€ no reports yetβš•οΈ no reports yet
  • PsychosisπŸ‘€ no reports yetβš•οΈ no reports yet
  • ManiaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Dependence / misuseπŸ‘€ no reports yetβš•οΈ no reports yet
  • ToleranceπŸ‘€ no reports yetβš•οΈ no reports yet
  • Serious cardiac eventπŸ‘€ no reports yetβš•οΈ no reports yet
  • Seizure/Epileptic fitπŸ‘€ no reports yetβš•οΈ no reports yet
  • HyperthermiaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Serotonin syndromeπŸ‘€ no reports yetβš•οΈ no reports yet
  • Withdrawal/Discontinuation SyndromeπŸ‘€ no reports yetβš•οΈ no reports yet

+ Add an effect

Pharmacokinetics

Metabolism

Hepatic metabolism includes N-demethylation to amphetamine (an active metabolite).

Elimination

Urinary elimination is pH-dependent.

Pharmacodynamics

Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.

Interactions

  • MAOIs β€” contraindicated (per label)
  • Acidifying agents β€” increase urinary clearance
  • Alkalinizing agents β€” decrease urinary clearance

    Pregnancy and lactation

Category C per Desoxyn label.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

Mixed amphetamine salts, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Dexmethylphenidate, Modafinil

References

Pharmacy
Starting dose
5 mg PO
Preparations
Desoxyn 5 mg tabs
US FDA Max
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
Common uses
Classification(s)
Classes
Psychostimulant, Amphetamine
Pharmacology
Routes
Oral (prescribed)
Pregnancy
Category C (per Desoxyn label)
Legal status
Schedule II
Purported mechanism
Monoamine releasing agent β€” TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport